Entera Bio Ltd. (NASDAQ: ENTX) filed a streamlined Phase 3 protocol, statistical analysis plan, and open‑label extension synopsis with the U.S. Food and Drug Administration as part of its IND 505(b)(2) submission for its oral parathyroid hormone tablet, EB613, on March 4 2026.
The new protocol is a multinational, randomized, double‑blind, placebo‑controlled study of 750 postmenopausal women. It replaces the previously planned 24‑month total hip bone mineral density (BMD) assessment with a 12‑month primary endpoint and advances the single‑tablet “Next‑Gen EB613” formulation into the Phase 3 trial, eliminating the need for bridging studies between the multi‑tablet and single‑tablet versions.
By gaining FDA acceptance of total hip BMD as a surrogate endpoint, Entera has shortened the expected timeline for topline results to the second half of 2028—about one year earlier than originally projected. The accelerated schedule could bring the first oral anabolic therapy for osteoporosis to market sooner, potentially capturing a large unmet need in a population that has limited options due to the inconvenience of injectable treatments.
Entera’s financial position remains a key consideration. The company has reported net losses in recent quarters, but its cash reserves are sufficient to fund operations through late 2026. Continued funding will be essential to support the Phase 3 trial and future development milestones, underscoring the importance of the regulatory milestone in maintaining investor confidence.
CEO Miranda Toledano emphasized the strategic significance of the submission, stating, “This submission marks a pivotal inflection point for Entera and potentially enables us to get EB613 to patients faster. Our goal with EB613 is to democratize anabolic treatment and enable millions of women and men to protect their bones earlier and potentially deter the catastrophic consequences of fracture.” The company’s insider buying activity in February 2026 and consistent analyst confidence further reinforce the positive outlook for the program.
Market reaction to the filing has been favorable, driven by the FDA’s agreement on the surrogate endpoint, the shortened development timeline, the single‑tablet formulation that simplifies commercialization, and the recent insider purchases that signal management confidence. Analysts have highlighted the potential for a significant market opportunity and the strategic advantage of an oral anabolic therapy in a field dominated by injectable products.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.